Evidence map›Paper›PMID 42395902›Full record

ArticleFrontiers in microbiology2026

Anti-SARS-CoV-2 VHH and C7C peptide fused with Angiopep-2 efficiently traverse blood-brain barrier model and neutralizes virus.

Mangesh Bhide, Katarina Bhide, Evelina Mochnacova, Jakub Viglasky, Diana Kosturikova, Amod Kulkarni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mangesh BhideLaboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Katarina Bhide *Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Evelina Mochnacova *Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Jakub ViglaskyLaboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Diana KosturikovaLaboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Amod KulkarniLaboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The therapy for SARS-CoV-2-related CNS infection relies on treating neuroinflammation and associated damage, rather than a specific antiviral. The lack of specific antiviral therapeutics is mainly attributed to the limited permeability of drugs across the blood-brain barrier. Methods: In this paper, we present a detailed pipeline for selecting VHHs (single variable domain of llama heavy chain antibody) and 7-mer cyclic peptides (C7C) from phage-display libraries that bind to the spike protein and SARS-CoV-2 virion. Soluble VHH and C7C peptides overexpressed in the Results and discussion: The best VHH and C7C candidates, VHH

Indexed as

Angiopep-2blood-brain barrierC7C peptidecombinatorial phage displaySARS-CoV-2VHHVHH-phage displayvirus neutralization

Identifiers

PMID42395902
PMCPMC13323710

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.